Tocilizumab and rituximab reduce relapse rates and disability progression in NMOSD, with tocilizumab provides extra benefits in MOGAD.

Objective Myelin oligodendrocyte glycoprotein-associated disorders (MOGADs) are a rare new neurological autoimmune disease with unclear pathogenesis. Since a linkage of the disease to the human ...

In people with multiple sclerosis (MS), lesions that get slowly bigger over time, potentially due to chronic inflammation, are associated with more myelin loss throughout the brain, a study found.

His research group has been particularly interested in a certain type of cell called oligodendrocytes, which are common in the brain and spinal cord. One of their functions is precisely to produce ...